^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Myelodysplastic Syndrome
    Drug:pevonedistat (MLN4924) (NEDD8 activating enzyme inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Takeda
    Title:

    Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

    Published date:
    07/30/2020
    Excerpt:
    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its investigational drug pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS).
    Secondary therapy:
    azacitidine